Nanjing Vazyme Biotech Balance Sheet Health
Financial Health criteria checks 4/6
Nanjing Vazyme Biotech has a total shareholder equity of CN¥4.0B and total debt of CN¥884.7M, which brings its debt-to-equity ratio to 22.1%. Its total assets and total liabilities are CN¥5.4B and CN¥1.4B respectively.
Key information
22.1%
Debt to equity ratio
CN¥884.67m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥3.04b |
| Equity | CN¥4.00b |
| Total liabilities | CN¥1.42b |
| Total assets | CN¥5.41b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 688105's short term assets (CN¥3.9B) exceed its short term liabilities (CN¥1.2B).
Long Term Liabilities: 688105's short term assets (CN¥3.9B) exceed its long term liabilities (CN¥234.8M).
Debt to Equity History and Analysis
Debt Level: 688105 has more cash than its total debt.
Reducing Debt: 688105's debt to equity ratio has increased from 18.5% to 22.1% over the past 5 years.
Debt Coverage: 688105's debt is well covered by operating cash flow (20.4%).
Interest Coverage: Insufficient data to determine if 688105's interest payments on its debt are well covered by EBIT.